Turning Dreams into Reality: Roche’s CD3 Bispecific Antibody Combined ADC Shows Exceptional Efficacy, Expanding the CD3 Bispecific ADC Concept
▎Trace Back Three years ago, when I wrote analyses on the CD3 bispecific antibody combined ADC, it was often considered an overly aggressive therapy. However, Roche has made significant explorations in this area. When the CD3/DLL3 ADC from Wuxi Biologics was released, many in the industry were puzzled, but there is no need for surprise. … Read more